{{chembox
| Verifiedfields = changed
| verifiedrevid =
| ImageFile = Lasinavir.svg
| ImageSize = 200
| IUPACName = ''tert''-butyl ''N''-[(2''S'',3''S'',5''R'')-3-hydroxy-6-<nowiki>[[</nowiki>(2''S'')-1-(2-methoxyethylamino)-3-methyl-1-oxobutan-2-yl]amino]-6-oxo-1-phenyl-5-[(2,3,4-trimethoxyphenyl)methyl]hexan-2-yl]carbamate
| OtherNames =

| Section1={{Chembox Identifiers
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 408297
| InChI = 1S/C35H53N3O9/c1-22(2)29(33(41)36-17-18-43-6)38-32(40)25(20-24-15-16-28(44-7)31(46-9)30(24)45-8)21-27(39)26(19-23-13-11-10-12-14-23)37-34(42)47-35(3,4)5/h10-16,22,25-27,29,39H,17-21H2,1-9H3,(H,36,41)(H,37,42)(H,38,40)/t25-,26+,27+,29+/m1/s1
| InChIKey = BEUUJDAEPJZWHM-COROXYKFSA-N
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = 
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 0QGV8237I3
| CASNo_Ref = {{cascite|correct|??}}
| CASNo = 175385-62-3
| PubChem = 464372
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL =
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG =
| SMILES = CC(C)[C@@H](C(=O)NCCOC)NC(=O)[C@H](CC1=C(C(=C(C=C1)OC)OC)OC)C[C@@H]([C@H](CC2=CC=CC=C2)NC(=O)OC(C)(C)C)O
}}

|Section2={{Chembox Properties
| Formula = C<sub>35</sub>H<sub>53</sub>N<sub>3</sub>O<sub>9</sub>
| MolarMass = 659.81 g/mol
| Appearance = 
| Density = 
| MeltingPt = 
| BoilingPt = 
| Solubility = 
  }}
|Section3={{Chembox Hazards
| MainHazards = 
| FlashPt = 
| AutoignitionPt = 
  }}
}}

'''Lasinavir''' ([[International Nonproprietary Name|INN]],<ref>{{cite journal|title=International Nonproprietary Names for Pharmaceutical Substances (INN). RECOMMENDED International Nonproprietary Names (Rec. INN): List 38|journal=WHO Drug Information|date=1997|volume=11|issue=3|page=170|url=http://www.who.int/medicines/publications/druginformation/innlists/RL38.pdf?ua=1|accessdate=25 November 2015|publisher=World Health Organization}}</ref> previously known as '''BMS-234475''' and '''CGP-61755''') is an experimental [[peptidomimetic]] [[Protease inhibitor (pharmacology)|protease inhibitor]] researched by [[Novartis]] and [[Bristol-Myers Squibb]] as a treatment for [[HIV/AIDS|HIV infection]]. It was originally discovered by Novartis at [[Basel]] (Switzerland).<ref>
{{US patent reference
 | number = 7348345 B2
 | y = 2008
 | m = 08
 | d = 02
 | inventor = James Patrick Dunn, Steven Swallow, Zachary Kevin Sweeney
 | title = Nonnucleoside reverse transcriptase inhibitors
}}</ref>
Its investigation was terminated after [[Phases of clinical research|Phase I]] on October 09, 2002.<ref>{{cite web|title=Drug Profile: Lasinavir|url=http://adisinsight.springer.com/drugs/800006772|website=AdisInsight|publisher=Adis International Ltd, part of Springer Science+Business Media|accessdate=25 November 2015}}</ref>

==References==
{{reflist}}

{{HIVpharm}}

[[Category:Abandoned drugs]]
[[Category:Alcohols]]
[[Category:Carboxamides]]
[[Category:Carbamates]]
[[Category:HIV protease inhibitors]]
[[Category:Tert-butyl compounds]]

{{antiinfective-drug-stub}}